Prevalence of Extended-spectrum β-lactamase (ESBL)-producing organisms is increasing in healthcare associated (HCA) institutions and community. We conducted a matched case-double control study to assess the risk factors for acquisition of these multi-drug resistant organisms (MDRO), in a cardiac center in Brazil. We studied two hundred and thirty-eight patients (58 cases). Two groups of comparison were included: control Group 1 (N=120), with patients without infection; and control Group 2 (N=70), with patients with infection by non-ESBL producers Klebsiella spp., E. coli or Proteus mirabilis. On multivariate analysis, risk factors for hospital acquisition of ESBL-producing organisms were as follows: previous use of second-generation cephalosporins (OR 5.73; 95% CI 1.30-25.31), fourth-generation cephalosporins (OR 3.62; 95% CI 1.24-10.53) and metronidazole (OR 11.68; 95% CI 1.20-114.00). Previous identification of MDRO (OR 8.98, 95% CI 1.61-50.18), number of days on antibiotic use (OR 1.12; 95% 1.04-1.20) was also independently associated with ESBL-producing organisms. Interestingly, the presence of other MDRO in ward (OR 0.30; 95% CI 0.13-0.71) was associated as a protector factor for ESBL identification. When there was a low consumption of third-generation cephalosporins and quinolones, the second-and fourth-generation cephalosporins and metronidazole were, associated with ESBL-producing bacteria. In addition, adherence to isolation precautions and infection control recommendations can help to prevent ESBL-resistance dissemination.
INTRODUCTION
Extended-spectrum β-lactamase (ESBL)-producing organisms pose a great challenge to epidemiologists, infection control practitioners and physicians 1, 2 . The dissemination of these broad spectrum resistant bacteria is difficult to control and the therapeutic options for severe infections are limited 1, 3, 4 The emergence of ESBL-producers bacteria is increasing in both hospitals and community 5 . This resistant mechanism is most found in Klebsiella pneumoniae in hospital and Escherichia coli in community as well 5, 6 .
There are several reasons for the increasing prevalence of these organisms in hospitals 4, 7 , such as, the selective pressure of antimicrobials overuse, the use of invasive devices, crosstransmission between patients, hospital cross-infection, and the increase in prevalence of community origin 6, 8, 9, 10 .
Infection by these organisms is associated with higher mortality rates 11, 12 . Carbapenems use is associated with lower mortality in patients with serious infections 8, 13 . Although other agents may be used in non-severe infected patients, this use must be viewed with caution 14, 15, 16, 17 We conduct a case control-study in a cardiac center in Brazil to identify risk factors for ESBL-producing organisms identification.
METHODS
A matched case-double control study was conducted at Instituto de Cardiologia, a 250-bed hospital for cardiology patients in southern Brazil. Instituto de Cardiologia attends adult and pediatric, surgical and clinical cardiology patients. In addition, the hospital has a cardiac transplant service, and three intensive care units (ICUs), which account for 16% of institution's beds.
Adult (age ≥ 18 years) inpatients were selected from the entire hospital irrespective of unit. Case patients were those with identification of ESBL-producing bacteria at any site, after 48 hours of admission. For this analysis, we included two control groups: Group 1 was composed of patients from hospital units but not with ESBL-producing organisms; and patients with non ESBL-producing composed Group 2 Klebsiella spp., Escherichia coli, or Proteus mirabilis. Controls were matched in terms of age (± 3 years), date of sample identification (± 3 days), gender, and hospital ward.
From January 2008 to December 2009 all ESBL-producing organisms were included (patient cases). Controls were selected in a rate 1:2 (Group 1): 1 (Group 2).
All samples were processed at the microbiology laboratory at Instituto de Cardiologia. Detection of ESBL-producing bacteria was made according to the National Committee for Clinical Laboratory and Standards guidelines 18 . The susceptibility to antibiotics used agar disc diffusion method tested. For detection ESBL-producing strains, Double-disc synergy test was used. Bacteria considered as multidrug resistant organism (MDRO) were as follows: methicillin resistant Staphylococcus aureus (MRSA), ESBL-producing Escherichia coli, Klebsiella spp., Proteus mirabilis, carbapenems resistant Acinetobacter baumanii and Pseudomonas aeruginosa, vancomycin resistant enterococci (VRE).
We reviewed data from patients' medical charts. Antibiotic use was measured for 24 months of study period, for the entire hospital. Data from prescribed drugs, such as, carbapenems, fluoroquinolones, cephalosporin's, piperacillin/tazobactam, vancomycin, ampicillin+sulbactam and oxacillin, metronidazole, clindamycin, sulfametoxazole+trimetoprrim were reviewed. Patient comorbidities, invasive devices use and surgical procedures, ICU admission, previous MDRO identification in the previous 90 days, previous hospital stay during the last year, and other than ESBL-producing MDRO identified in patient ward were also reviewed.
Previous antibiotic use was at least 48h of inpatient use in the current admission. Time-at-risk is defined as the duration of time between admission and the detection of the antibioticresistant organism on culture for cases; as the number of days between admission and detection of the susceptible organism on culture, for non-resistant enterobactereacea infected controls; and the time between admission and discharge for noninfected control patients. Antibiotic consumption counted a number of defined daily doses (DDD), expressed as DDD per 100 patient-days. Central venous catheter (CVC), urinary catheterization, and mechanical ventilation were considered as invasive devices.
A descriptive analysis of the variables collected from each patient was performed. The chi-squared test or Fisher's exact test were used for univariate analysis of selected cat-egorical variables. All odds ratios on univariate analysis were controlled for time at risk exposure. Associations were considered statistically significant when P value was ≤.05. Multivariate analysis, along with 95% confidence intervals (CI) and Odds ratios were calculated using the Logistic regression model. We divided the analysis in three models. The first model included the risk factors other than specific antimicrobials that were statistically significant on univariate analysis; the second model included the antimicrobials with statistical significance on univariate analysis and days on antimicrobial use. The final model included the variables that were statistically significant in the first two models. All analysis was corrected for time at risk. All collected data was stored in Excel ® 2000 version and analyzed using SPSS ® 18.0 program.
The research and ethics committee of Fundação Universitária de Cardiologia (Brasil) approved the study and waived the need for informed consent because of the nature of the study.
RESULTS
Patient characteristics are shown in Table 1 . Through the study period, we included fifty-eight case patients. Most of them infected with Klebsiella spp. (65.5%; N=38). The rest of patients were infected with Proteus spp. (25.9%; N=15) and E. coli (8.6%; N=5). Control Group 2, were composed by 70 patients with identification of non ESBL-producing Klebsiella spp. (85.7%; N=60), Proteus spp. (10.0%; N=7), and E. coli (4.3%; N=3). One hundred and twenty patients were included in control Group 1.
Most patients were at general ward (55.2%; N=137); 26.6% (N=66) at post-surgical ward; 15.7% (N=39) at ICU; and 2.4% (N=6) were at emergency department. From case patients, most specimens were from urinary tract (39.6%; N=23), respiratory tract (32.8%; N=19), and surgical wound (12.1%; N=7). From control group 2 sites of specimen identification were as follows: respiratory tract (45.7%; N=32), urine (31.4%; N=22), blood culture (10.0%; N=7), and surgical wound (7.1%; N=5). 
DISCUSSION
To answer the question "What are the risk factors for acquiring ESBL-producers pathogen among hospitalized patients?" Our study concluded that the second-generation cephalosporins, metronidazole, days on antibiotic use and previous MDRO other than ESBL were independently associated with ESBL-producer. For the question "What are the risk factors for developing ESBL-producers pathogen among patients with non-ESBL Klebsiella spp. E. coli, and Proteus spp.?" The answer was the second-and fourth generation cephalosporins, previous identification of a MDRO other than ESBL, and, interestingly, the presence of other MDRO in ward were associated with protection form ESBLproducers identification.
In our setting where there is a high consumption of cephalosporins, especially fourth-generation cephalosporins, but a low consumption of third-generation cephalosporin and quinolones, use of second-and fourth-generation cephalosporins were associated with ESBL production. Besides the use of piperacillin+tazobactam was not associated with ESBL production. The hospital antimicrobial stewardship program (ASP) recommends the use of fourth-and second-instead of the third-generation cephalosporins and quinolones, because the associated risk of resistance linked to these drugs 19, 20 . Besides the use of penicilins and piperacillin+tazobactam are stimulated, the carbapenems are the drugs reserved for infection by ESBL-producers 21, 22 .
A variety of antimicrobial classes and antimicrobial drugs have been associated with ESBL-production in bacteria 23, 24 . Cephalosporins, especially third-generation cephalosporins, fourth-generation cephalosporins, the quinolones, piperacillin+tazobactam, vancomycin, penicilins and beta-lactamase-inhibitors penicilins, and gentamicin all have been linked to ESBL-producing bugs 25 . Although a few studies have assessed important methodological principles like those that control group selection derived from appropriate sampling of the base population, time at risk and comorbid illnesses for studies on ESBL resistance.
Behar et al, evaluated risk factors for ESBL resistance in
Klebsiella pneumoniae in four different groups of comparisons, with two types of controls: non-resistant Klebsiella pneumoniae and patients without infection derived from the same source of cases 26 . They found the cephalosporins use as a consistent risk factor. Besides, time at risk and CVC use were also identified as risk factors.
Furthermore, Odds ratios were slightly higher considering antimicrobial use in the comparison between case and control Group 2, as stated by others. Furthermore, the cephalosporins as risk factors confirms the risk associated with ESBL-producers, however, our study confirms that secondand fourth-generation cephalosporins can also be related to ESBL-resistance in a setting of low use of other cephalosporins. In addition, this is the first study to link metronidazole use to ESBL-producers. Interestingly, this association was only seen in control group 1. We speculate that this might be related to the suppression of intestinal anaerobic flora and the rise of resistant enterobactereacea. The use of other antimicrobial with activity against anaerobes like meropenem, ampicillin+sulbactam, and piperacillin+tazobactam were not related to resistance probably because enterobactereacea suppression flora too 20 .
A few institutions implemented the use of piperacillin+tazobactam intended to reduce ESBL-producers. Other independently factors associated with ESBL were: previous MDRO isolation and days on antibiotic use. Interestingly, the presence of any MDRO in case patient ward was a protector factor for identification of ESBL-resistance, a group from Baltimore suggests that patient-to-patient transmission is not an important cause of the acquisition of ESBL-producing 27 . Although, we have not studied the association between adherence to contact precautions and resistance, we suppose that with the identification of a MDRO other than ESBL-producers in the ward, the implementation of contact precautions protected other patients from ESBLproducing bacteria. In our hospital, most general wards were composed of three to five patients dividing the same room.
Control-group selection in antimicrobial resistant studies is of great importance 26 . As recommended, we choose to include controls selected from the same unit of cases patients that were in hospital in a period near to the case patient resistant bacteria identification. Besides, using two control groups we try to control for the selection bias that arises when only antimicrobial-susceptible organisms are used as control patients 28 . Although we could not include in the final analysis a severity score for our patients, the inclusion of comorbities that were statistically related to the outcome on univariate analysis and the adjustments for time-at-risk on multivariate analysis could reduce bias to this confounding. Patients admitted for longer periods are more likely to receive a greater number of antibiotics 20 . In addition, time-at-risk correlates with illness severity.
CONCLUSION
Our study has some limitations: our patients are from a specific cardiac center, which caused difficult generalization of results. We could not study the mechanisms of resistance in our patients. Our patients' selection was based on clinical specimens collected as decision from the attending physician. We did not systematically collected surveillance samples, this way we could not ascertain about previous colonization.
In order to review our antimicrobial policy we aim to investigate which specific antimicrobial or other risk factor was associated with ESBL-producing bacteria. Although cefepime and cefuroxime have been used for preserving third-generation cephalosporins, they were also associated with ESBLresistance 29 . The implementation of contact precautions and a strict adherence to this measure contributes to the control of resistance in our setting 30 . 
